Manufacturer and R&D manufacturer of lpilimumab

Ipilimumab (Ipilimumab) is produced and developed by the American pharmaceutical company Bristol-Myers Squibb (Bristol-Myers Squibb, now known as Bristol Myers Squibb). The company is a leading global biopharmaceutical company focused on the development and production of innovative drugs, especially immunotherapy drugs in the field of cancer.

Ipilimumab was first developed by the American biotechnology company Medarex and later Medarex was acquired by Bristol-Myers Squibb. Bristol-Myers Squibb played a key role in bringing ipilimumab to the market. This drug was approved by the U.S. Food and Drug Administration (FDA) in 2011, becoming the first FDA-approved CTLA-4 inhibitor for the treatment of malignant melanoma (melanoma).

Since then, research and clinical trials of ipilimumab have continued, not only achieving success in the treatment of melanoma, but also extending to the treatment of other tumor types, such as advanced colorectal cancer. It is often used with other immunotherapy drugs, such as nivolumab, to increase the effectiveness of immunotherapy.

In summary, the production and development of ipilimumab is managed by Bristol-Myers Squibb. This drug represents an important advance in the field of immunotherapy, providing new prospects for cancer treatment and improving the survival and quality of life of many patients.

Ipilimumab is not currently available in China, so patients cannot purchase it domestically and can only purchase it through overseas purchase channels. There are only original drugs of Ipilimumab abroad, mainly Turkish original drugs and Bristol-Myers Squibb original drugs. The price of Turkish original drugs is around 12,000 yuan, and the specification is 50mg/10ml; Bristol-Myers Squibb-The price of Bristol-Myers Squibb original drug is about11,700 yuan, and the specification is also50mg/10ml, the two drugs have the same ingredients.